EMEA-001191-PIP01-11-M03 - paediatric investigation plan

Daclatasvir
PIPHuman

Key facts

Invented name
Daklinza
Active Substance
Daclatasvir
Therapeutic area
Infectious diseases
Decision number
P/0367/2019
PIP number
EMEA-001191-PIP01-11-M03
Pharmaceutical form(s)
  • Chewable tablet
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of chronic hepatitis C
Route(s) of administration
Oral use
Contact for public enquiries

Bristol-Myers Squibb Pharma EEIG 
E-mail: medical.information@bms.com 
Tel. +44 (0)1423 533610

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page